| I-22 Linda Aulin Physiologically-based pharmacokinetic model to predict lung distribution of anti-infective agents Wednesday 09:50-11:15 |
| I-27 Vanessa Baier Assessing the cholestatic potential of drugs using a physiology-based model of the bile acid metabolism Wednesday 09:50-11:15 |
| I-28 Pavel Balazki A mechanistic model of gastric emptying of caloric liquids and solids for the use in physiologically-based pharmacokinetics models. Wednesday 09:50-11:15 |
| I-82 Mailys De Sousa Mendes Transporter inhibition: modelling in-vitro Transwell assays Wednesday 09:50-11:15 |
| II-06 Jennifer Lang Combining physiologically-based-pharmacokinetic modelling and a Bayesian method for prediction of ivabradine oral absorption and drug-drug interactions Wednesday 15:10-16:40 |
| II-15 Anja Lehmann Toxicokinetic modelling of hepatotoxic pyrrolizidine alkaloids: a combined in silico, in vitro and in vivo approach Wednesday 15:10-16:40 |
| II-28 Ulrich Ruben Luecht Physiologically based pharmacokinetic modeling approach to assess drug-drug interactions (DDI) between psychopharmaceuticals – focus on mirtazapine and venlafaxine Wednesday 15:10-16:40 |
| II-33 Panos Macheras On the unphysical hypotheses in pharmacokinetics and oral drug absorption:Time to utilize instantaneous rate coefficients instead of rate constants Wednesday 15:10-16:40 |
| II-39 Fatima Zahra Marok Physiologically-based pharmacokinetic modeling of DPYD substrate 5-fluorouracil and its prodrug capecitabine Wednesday 15:10-16:40 |
| II-40 Frederico Martins Application of Physiologically Based Pharmacokinetic (PBPK) Modelling to Support First in Human dose selection. Wednesday 15:10-16:40 |
| II-44 Nicola Melillo Global sensitivity analysis of a physiologically based pulmonary absorption model Wednesday 15:10-16:40 |
| II-51 Daniel Moj Biotest’s Pentaglobin® in adults and neonates (term and preterm) – A PBPK approach Wednesday 15:10-16:40 |
| II-82 Luna Prieto Garcia Physiologically-based pharmacokinetic model for itraconazole and its metabolites: the importance of parameter sensitivity analysis Wednesday 15:10-16:40 |
| II-84 Rajith Rajoli PBPK Modelling of Atovaquone Long-acting Injectable Formulations Wednesday 15:10-16:40 |
| III-13 Annika Schneider A PBPK approach for simulating the effect of liver cirrhosis on drug PK Thursday 09:55-11:20 |
| III-16 Dmitry Shchelokov Physiologically based pharmacokinetic modeling of anti-PD-1 therapeutic antibodies Thursday 09:55-11:20 |
| III-17 Soyoung Shin Novel population approach to establish in vitro-in vivo correlation for drugs with site-dependent absorption Thursday 09:55-11:20 |
| III-20 Florian Simon A generic PBPK model for predicting the impact of inflammation on midazolam pharmacokinetics Thursday 09:55-11:20 |
| III-47 Denise Feick Physiologically-based pharmacokinetic modeling of the CYP2C8 perpetrator trimethoprim Thursday 09:55-11:20 |
| III-62 Ludwig Vincent How to improve the accuracy of Drug-Drug Interaction risk prediction for Mechanism Based Inhibitors Thursday 09:55-11:20 |
| III-69 Shayne Watson Development and Evaluation of a Human Physiologically Based Pharmacokinetic Model to Assess a Mitigation Strategy for Risks Associated with Novel Monoclonal Antibodies Thursday 09:55-11:20 |
| III-78 Jan-Georg Wojtyniak Physiologically-based Pharmaokinetic Modelling of Metoprolol Drug-Drug-Gene Interactions with Paroxetine and CYP2D6 Thursday 09:55-11:20 |
| III-82 Estelle Yau A global sensitivity analysis of the Rodgers and Rowland equations predicting drug distribution in PBPK models Thursday 09:55-11:20 |
| IV-08 Esther Encinas Use of modeling and simulation methods to support the generic application of a vaginal delivery system Thursday 15:25-16:50 |
| IV-15 Rebekka Fendt Evaluating the benefit of individual patient data for physiologically based pharmacokinetic (PBPK) simulations Thursday 15:25-16:50 |
| IV-21 Laura Fuhr Physiologically based pharmacokinetic modeling of the dabigatran antidote idarucizumab Thursday 15:25-16:50 |
| IV-24 Fiona G. Gao Prediction of human pharmacokinetics of subcutaneously administered insulin formulations Thursday 15:25-16:50 |
| IV-36 Silvia Grandoni Development and evaluation of a PBPK model to study the pharmacokinetics of inhaled drugs in rats Thursday 15:25-16:50 |
| IV-49 Lukas Kovar Physiologically-based pharmacokinetic (PBPK) modelling of nicotine and its main metabolite cotinine in healthy volunteers and smokers Thursday 15:25-16:50 |
| IV-50 Anneke Himstedt Prediction of pulmonary exposure based on plasma pharmacokinetics: A comparison of different model-based approaches. Thursday 15:25-16:50 |
| IV-87 Lisa Alina Kneller Impact of Cytochrome P450 2D6, -3A4 and P-glycoprotein on Risperidone’s and 9-Hydroxyrisperidone’s plasma concentrations using a whole-body PBPK approach Thursday 15:25-16:50 |
